TY  - JOUR
A1  - Mansour, Ahmad M.
A1  - Arevalo, J. Fernando
A1  - Al Kahtani, Eman
A1  - Zegarra, Hernando
A1  - Abboud, Emad
A1  - Anand, Rajiv
A1  - Ahmadieh, Hamid
A1  - Sisk, Robert A.
A1  - Mirza, Salman
A1  - Tuncer, Samuray
A1  - Navea Tejerina, Amparo
A1  - Mataix, Jorge
A1  - Ascaso, Francisco J.
A1  - Pulido, Jose S.
A1  - Guthoff, Rainer
A1  - Goebel, Winfried
A1  - Roh, Young Jung
A1  - Banker, Alay S.
A1  - Gentile, Ronald C.
A1  - Alonso Martinez, Isabel
A1  - Morris, Rodney
A1  - Panday, Neeraj
A1  - Min, Park Jung
A1  - Merce, Emilie
A1  - Lai, Timothy Y. Y.
A1  - Massoud, Vicky
A1  - Ghazi, Nicola G.
T1  - Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma
JF  - Journal of Ophtamology
N2  - We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15; P = 0.001), 105.3 microns at 1 year (n = 10; P = 0.03), and 157.6 microns at 2 years (n = 7; P = 0.08). BCVA improved by 3.3 lines at 6 months after therapy (n = 26; P < 0.001), 2.8 lines (n = 20; P = 0.01) at 1 year, and 3.1 lines (n = 13; P = 0.049) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.
KW  - membrane
KW  - photodynamic therapy
KW  - secondary
KW  - bevacizumab
KW  - ranibizumab
KW  - patient
Y1  - 2014
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-117923
IS  - 210458
ER  - 
TY  - JOUR
A1  - Bahena, Paulina
A1  - Daftarian, Narsis
A1  - Maroofian, Reza
A1  - Linares, Paola
A1  - Villalobos, Daniel
A1  - Mirrahimi, Mehraban
A1  - Rad, Aboulfazl
A1  - Doll, Julia
A1  - Hofrichter, Michaela A. H.
A1  - Koparir, Asuman
A1  - Röder, Tabea
A1  - Han, Seungbin
A1  - Sabbaghi, Hamideh
A1  - Ahmadieh, Hamid
A1  - Behboudi, Hassan
A1  - Villanueva-Mendoza, Cristina
A1  - Cortés-Gonzalez, Vianney
A1  - Zamora-Ortiz, Rocio
A1  - Kohl, Susanne
A1  - Kuehlewein, Laura
A1  - Darvish, Hossein
A1  - Alehabib, Elham
A1  - La Arenas-Sordo, Maria de Luz
A1  - Suri, Fatemeh
A1  - Vona, Barbara
A1  - Haaf, Thomas
T1  - Unraveling the genetic complexities of combined retinal dystrophy and hearing impairment
JF  - Human Genetics
N2  - Usher syndrome, the most prevalent cause of combined hereditary vision and hearing impairment, is clinically and genetically heterogeneous. Moreover, several conditions with phenotypes overlapping Usher syndrome have been described. This makes the molecular diagnosis of hereditary deaf-blindness challenging. Here, we performed exome sequencing and analysis on 7 Mexican and 52 Iranian probands with combined retinal degeneration and hearing impairment (without intellectual disability). Clinical assessment involved ophthalmological examination and hearing loss questionnaire. Usher syndrome, most frequently due to biallelic variants in MYO7A (USH1B in 16 probands), USH2A (17 probands), and ADGRV1 (USH2C in 7 probands), was diagnosed in 44 of 59 (75%) unrelated probands. Almost half of the identified variants were novel. Nine of 59 (15%) probands displayed other genetic entities with dual sensory impairment, including Alström syndrome (3 patients), cone-rod dystrophy and hearing loss 1 (2 probands), and Heimler syndrome (1 patient). Unexpected findings included one proband each with Scheie syndrome, coenzyme Q10 deficiency, and pseudoxanthoma elasticum. In four probands, including three Usher cases, dual sensory impairment was either modified/aggravated or caused by variants in distinct genes associated with retinal degeneration and/or hearing loss. The overall diagnostic yield of whole exome analysis in our deaf-blind cohort was 92%. Two (3%) probands were partially solved and only 3 (5%) remained without any molecular diagnosis. In many cases, the molecular diagnosis is important to guide genetic counseling, to support prognostic outcomes and decisions with currently available and evolving treatment modalities.
KW  - Usher syndrome
KW  - hearing impairment
KW  - combined retinal dystrophy
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-267750
SN  - 1432-1203
VL  - 141
IS  - 3-4
ER  -